Syndax Pharmaceuticals SNDX Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Syndax Pharmaceuticals's cash provided by (used in) financing activity, including discontinued operation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Syndax Pharmaceuticals's cash provided by (used in) financing activity, including discontinued operation?
- Syndax Pharmaceuticals (SNDX) reported cash provided by (used in) financing activity, including discontinued operation of $7.92M in Q1 2026.
- How has Syndax Pharmaceuticals's cash provided by (used in) financing activity, including discontinued operation changed year-over-year?
- Syndax Pharmaceuticals's cash provided by (used in) financing activity, including discontinued operation increased by 751.4% year-over-year, from $930K to $7.92M.
- What is the long-term trend for Syndax Pharmaceuticals's cash provided by (used in) financing activity, including discontinued operation?
- Over 4 years (2021 to 2025), Syndax Pharmaceuticals's cash provided by (used in) financing activity, including discontinued operation has grown at a -41.7% compound annual growth rate (CAGR), from $118.46M to $13.68M.
- What does cash provided by (used in) financing activity, including discontinued operation mean?
- This metric measures the net cash flow between the company and its capital providers, including proceeds from debt or equity issuance and payments for dividends or share repurchases. It highlights how the company finances its operations and returns value to shareholders.